New HIV Frontier: The Fight To Access Long-Acting Prevention Drugs - Health Policy Watch
Last month, Médecins sans Frontières (MSF) launched a campaign to demand that the US-based Gilead “immediately make the highly effective HIV prevention
Brazilian Health Minister Dr Alexandre Padilha RIO DE JANEIRO – News that an antiretroviral drug injected twice a year had prevented almost all HIV infection in trials electrified the HIV sector two years ago – but access to Gilead’s lenacapavir has been slow, particularly for countries in Latin America. Brazil, which faces significant HIV transmission in certain groups, has been routinely excluded from HIV voluntary licensing deals offered by pharmaceutical companies – particularly for long-acting pre-exposure prophylaxis (PrEP) – as it is deemed an upper-middle-income country. Brazilian Heal
Explore this link on the map →related reading
- FDA approves lenacapavir as a twice-a-year shot to prevent HIV | AP Newsapnews.com
- Why we didn't get a malaria vaccine sooner - Works in Progress Magazineworksinprogress.co
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- How To Save Twenty Million Lives, with Dr. Mark Dybulstatecraft.pub
- Ophelia Dahl’s National Health Service | The New Yorkernewyorker.com
- How Advocates Pushed Big Pharma to Cut Tuberculosis Drug Prices | Scientific Americanscientificamerican.com
- Bill Gates, Vaccine Monster | The New Republicnewrepublic.com
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- Vaginal Drug Delivery Had A Funding Problem—Merck Changed Thatforbes.com
- The Island Where People Go to Cheat Death | The New Republicnewrepublic.com
- Why are our medicines so expensive? Spoiler: Not for the reasons you are being told… - PMCncbi.nlm.nih.gov
- HIV epidemic in the Philippines: The 2nd wave | Xtra Magazinextramagazine.com